Search results
Results from the WOW.Com Content Network
At the beginning of 2011, DePuy Orthopaedics said they were phasing out the ASR Hip Implant because of declining sales, but never mentioned the high failure rate data from an Australian implant registry. In March 2011, The New York Times reported that DePuy issued its first warning to doctors and patients about the high early failure rate. [1]
Metallosis is the medical condition involving deposition and build-up of metal debris in the soft tissues of the body. [ 1] Metallosis has been known to occur when metallic components in medical implants, specifically joint replacements, abrade against one another. [ 1] Metallosis has also been observed in some patients either sensitive to the ...
Following the 2010 DePuy Hip Recall, Lanier represented plaintiffs in several lawsuits against Johnson & Johnson and DePuy Synthes, which Johnson & Johnson acquired in 1998. [16] The implants were said to cause a build-up of metal ions in the blood, causing groin pain, allergic reactions, bone erosion and tissue death. [17]
Johnson & Johnson and its DePuy Orthopaedics unit have agreed to pay $120 million to resolve deceptive marketing claims by several U.S. states. J&J, U.S. states settle hip implant claims for $120 ...
In a letter to J&J's DePuy Orthopaedics, ... the Corail Hip System, was cleared, the FDA says, and indicated for cementless use only. ... It expects the effects of the recall to be $600 million ...
On August 24, 2010, DePuy recalled [4] all ASR hip implant systems sold since 2003. The 2010 DePuy Hip Recall was issued after research released by the National Joint Registry (NJR) found high rates of hip replacement failure for the ASR XL Acetabular and ASR Hip Resurfacing systems.
The FDA said the recall of the device BioZorb Marker, initiated by Hologic in March, was not a product removal, but a correction. The agency also urged patients to report any side effects they ...
the Government’s recent investigations of several manufacturers of hip and knee surgical implants offer some insight. In 2005, the orthopedic device market for hips and knees witnessed domestic sales in excess of $5.1 billion and worldwide sales of more than $9.4 billion. We found that during the years 2002 through 2006, four manufacturers (which